10179 Huennekens Street
Tel: (858) 283-3926
About Adagene Incorporated
Adagene is a publicly traded, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer.
Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients. Our discovery engine, Dynamic Precision Library, is driving Adagene’s pipeline of programs with potential to be first or best in class.
We have forged strategic partnerships with multiple reputable global companies. These partnerships leverage our technology in approaches at the vanguard of science, including safer precision-guided antibody-drug conjugates and transformative antibody design.
Founded and led by world-class leaders in antibody discovery and engineering, Adagene is well-positioned to address unmet needs in areas where other treatments have had little or no success.
Are you interested in joining a global team of dedicated professionals working to transform discovery and development of antibody therapeutics? Adagene is a high growth global company with operations in China, U.S., Singapore and Australia. We are looking for talented, self-motivated individuals who share our passion to improve the lives of patients around the world.
50 articles with Adagene Incorporated
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
Adagene Inc., a company transforming the discovery and development of antibody-based therapies, announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board.
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
Adagene Inc. announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update at the Biotech Showcase™ 2023, taking place January 9-11th in San Francisco, in parallel to the annual J.P. Morgan Healthcare Conference.
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
Adagene Inc., a company transforming the discovery and development of antibody-based therapies, announced the appointment of Cuong Do, MBA, to Adagene’s board of directors as an independent director.
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced the publication of data showing the best-in-class potential of ADG126, a masked, anti-CTLA-4 SAFEbody®.
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
Adagene Inc. announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$10 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended, and the Company’s insider trading policy.
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced the publication of data showing the potential best-in-class safety profile of its anti-CTLA-4 monoclonal antibody, ADG126.
Adagene to Participate in Investor Conferences in May and June 2022
Adagene Inc. announced that members of the company’s management will participate in the following upcoming investor conferences.
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced preclinical data showcasing the potential first and best-in-class profile of new antibody candidates.
It was a busy week for clinical trial announcements. Here's a look.
Several biopharma companies celebrate the U.S. Food and Drug Administration’s approval for clinical trials involving therapeutics for cancer treatment.
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with the anti-PD-1 antibody pembrolizumab.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced publication of four abstracts featuring preclinical data from its expanding pipeline in advance of the AACR Annual Meeting 2022 in New Orleans, Louisiana from April 8-13, 2022.
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
Adagene Inc. announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Shares of Adagene Inc. are up more than 10% in premarket trading after the company announced a monoclonal and bispecific antibody collaboration with Sanofi valued at up to $2.5 billion.
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Adagene Inc. announced that members of the company’s management will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.
Adagene Announces Board and Management Appointments to Support Pipeline Growth
Adagene Inc., a company transforming the discovery and development of antibody-based therapies, announced board and management appointments aimed at supporting the company’s pipeline growth and corporate development.
Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116
Adagene Inc. today announced the first patient has been dosed in a combination cohort of its anti-CD137 agonist, ADG106, with its anti-CTLA-4 monoclonal antibody (mAb), ADG116, in patients with advanced/metastatic solid tumors.
Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.
Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development.
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore
Adagene Inc. announced that the first patients have been dosed in a phase 1b/2 clinical trial of the anti-CD137 agonist antibody, ADG106, in combination with the anti-PD-1 antibody, Nivolumab for patients with advanced non-small cell lung cancer who have progressed on prior therapies.